Impact of endobiliary radiofrequency ablation for locally advanced cholangiocarcinoma

Impact of endobiliary radiofrequency ablation before neoadjuvant chemotherapy in patients with initially unresectable locally advanced cholangiocarcinoma: A randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0009852

Enrollment

Registered

2024-10-16

Start date

2024-09-10

Completion date

Unknown

Last updated

2024-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : 1) Study Design This study targets patients with initially unresectable locally advanced cholangiocarcinoma requiring neoadjuvant chemotherapy. Patients will be randomly assigned into

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Inclusion Criteria Patients aged 19 to 79 years Patients with initially unresectable locally advanced cholangiocarcinoma An expected survival duration of at least 3 months Performance status: ECOG 0-1 or Karnofsky performance score > 80%

Exclusion criteria

Exclusion criteria: 2) Exclusion Criteria Patients with uncontrolled coagulation disorders (INR > 1.5 or platelet count < 50,000/mm³) Pregnant or breastfeeding patients Patients with anatomically altered biliary structures due to previous surgical interventions Patients who are unsuitable for endoscopic retrograde cholangiopancreatography (ERCP)

Design outcomes

Primary

Measure	Time frame
resectability rate	—

Secondary

Measure	Time frame
Technical success of RFA;Clinical success of endobiliary RFA;Overall survival;Adverse event	—

Countries

Korea, Republic of

Contacts

Public ContactIl Sang Shin

Soon Chun Hyang University Hospital Bucheon

110554@schmc.ac.kr+82-32-621-5094

Outcome results